健友股份子公司产品注射用达巴万星获得美国FDA批准

Core Viewpoint - The company announced that its subsidiary, Jianjin Pharmaceutical Co., Ltd., received ANDA approval from the U.S. FDA for its injectable Dapavansine, 500mg/vial, for treating acute bacterial skin and skin structure infections in adults and pediatric patients [1] Group 1 - The ANDA number for the approved product is 218929 [1] - The approval expands the company's product offerings in the U.S. market [1] - The indication covers both adult and pediatric patients, indicating a broad potential market [1]